Liu Tinghua, Zhao Jiani, Sun Jinjian, Wu Kemin, Wang Wei
Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Front Cardiovasc Med. 2023 Dec 15;10:1257628. doi: 10.3389/fcvm.2023.1257628. eCollection 2023.
The objective of this study was to perform a network meta-analysis (NMA) to assess the efficacy and safety of three different surgical interventions- open surgical repair (OSR), hybrid surgical repair (HSR), and endovascular repair (EVAR)- for the treatment of thoracoabdominal aortic aneurysms (TAAAs).
Electronic repositories like PubMed, Embase, Web of Science, Scopus, ScienceDirect, the Cochrane library, Clinical trial, and China National Knowledge Infrastructure (CNKI) were systematically searched to identify studies that compared the efficacy of OSR, HSR, and EVAR with endografts for the treatment of TAAAs until December 24th, 2022. Random-effects and fixed-effects models were employed to analyze the data gathered in a network meta-analysis. The study's primary outcomes of interest encompassed in-hospital mortality, long-term survival rate, and postoperative complications.
Eleven comparative studies meet inclusion criterias. There were 2,222 patients in OSR, 1,574 patients in EVAR and 537 patients in HSR. EVAR has lower one-month mortality than OSR (RR: 0.31; 95% CI: 0.17-0.70) and HSR (RR: 0.37; 95% CI: 0.22-0.71), and lower incident rate of renal complications than HSR (RR: 0.20; 95% CI: 0.08-0.43) and OSR (RR: 0.34; 95% CI: 0.16-0.65). Nonetheless, there was no noteworthy discrepancy identified in the long-term survival rates of these procedures.
As compared with OSR, HSR, and EVAR, EVER has lower one-month mortality, and lower incident rates of complications.
PROSPERO (CRD42022313829).
本研究旨在进行一项网络荟萃分析(NMA),以评估三种不同手术干预方式——开放手术修复(OSR)、杂交手术修复(HSR)和血管腔内修复(EVAR)——治疗胸腹主动脉瘤(TAAA)的疗效和安全性。
系统检索了电子数据库,如PubMed、Embase、Web of Science、Scopus、ScienceDirect、Cochrane图书馆、临床试验数据库和中国知网(CNKI),以识别比较OSR、HSR和EVAR与腔内移植物治疗TAAA疗效的研究,检索截至2022年12月24日。采用随机效应模型和固定效应模型分析网络荟萃分析中收集的数据。本研究关注的主要结局包括住院死亡率、长期生存率和术后并发症。
11项比较研究符合纳入标准。OSR组有2222例患者,EVAR组有1574例患者,HSR组有537例患者。EVAR的1个月死亡率低于OSR(RR:0.31;95%CI:0.17 - 0.70)和HSR(RR:0.37;95%CI:0.22 - 0.71),且肾脏并发症发生率低于HSR(RR:0.20;95%CI:0.08 - 0.43)和OSR(RR:0.34;95%CI:0.16 - 0.65)。然而,这些手术方式的长期生存率没有显著差异。
与OSR、HSR相比,EVAR的1个月死亡率更低,并发症发生率也更低。
PROSPERO(CRD42022313829)